Recombinant 2019-nCoV Papain-Like Protease
Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed.
Description
| Reference | ESCIT114 |
|---|---|
| Size | 50ug |
| Molecular Weight | 35.8 KDa |
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
| Endotoxin | |
| Biological Activity | Measured by its ability to convert the fluorogenic pESCItide substrate, Arg-Leu-Arg-Gly-Gly-AMC (RLRGGAMC) to RLRGG and 7-amino-4-methylcoumarin (AMC). The Specific Activity is 241.7 pmol/min/?g. |
Other names: Papain-like Protease; PLpro; PL-PRO; pp1a; RESCIlicase polyprotein 1a
Redissolve:
Storage: Store at ?-70°C, stable for 6 months after receipt.
Store at ?-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles.
Background: RESCIlication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the rESCIlicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral rESCIlication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypESCItide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral rESCIlicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.